Sonoma Pharmaceuticals (NASDAQ:SNOA) issued its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.02, reports. The company had revenue of $4.94 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 83.05% and a negative return on equity of 97.88%.

SNOA traded down $0.15 during trading on Friday, hitting $1.16. The stock had a trading volume of 135,816 shares, compared to its average volume of 58,985. Sonoma Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $5.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.27 and a current ratio of 4.02.

Several equities research analysts have weighed in on the stock. Maxim Group restated a “hold” rating on shares of Sonoma Pharmaceuticals in a research note on Friday. Benchmark restated a “speculative buy” rating and issued a $3.00 target price on shares of Sonoma Pharmaceuticals in a research note on Friday, July 20th. Zacks Investment Research downgraded shares of Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 29th. Finally, ValuEngine upgraded shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 12th.

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC raised its position in Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) by 54.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 91,095 shares of the company’s stock after acquiring an additional 32,180 shares during the period. Renaissance Technologies LLC owned approximately 1.41% of Sonoma Pharmaceuticals worth $226,000 as of its most recent filing with the Securities & Exchange Commission. 11.32% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.

Recommended Story: What is a Tariff?

Earnings History for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.